Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation

被引：52

作者：

Boden G. ^{[1
]}

Rao A.K. ^{[1
]}

机构：

[1] Division of Endocrinology/Diabetes/Metabolism, Clinical Research Center, Temple University Hospital, Philadelphia, PA 19140

来源：

Current Diabetes Reports | 2007年 / 7卷 / 3期

基金：

美国国家卫生研究院;

关键词：

High Glucose; Tissue Factor; Cilostazol; High Insulin; Arterioscler Thromb Vasc Biol;

D O I：

10.1007/s11892-007-0035-1

中图分类号：

学科分类号：

摘要：

Tissue factor (TF) is the primary initiator of blood coagulation. Circulating TF procogulant activity (TF-PCA) is associated with blood cells and microparticles and is elevated in patients with type 2 diabetes mellitus. Combined hyperinsulinemia and hyperglycemia and to a lesser degree selective hyperinsulinemia for 24 hours in healthy volunteers increased circulating TF-PCA, monocyte TF surface expression and mRNA, plasma thrombin generation, and coagulation factors VII and VIII activities, suggesting that the coagulation system had been activated. In addition, platelet CD40L and platelet-monocyte aggregates increased, indicating platelet activation. Somostatin abolished these changes. We conclude that hyperinsulinemia, but particularly the combination of and hyperglycemia and hyperglycemia, creates a prothrombotic state and may, in addition, be proinflammatory and proatherogenic by virtue of actions of CD40L and TF. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：223 / 227

页数：4

共 30 条

[1]

Pan W.H., Cedres L.B., Liu K., Et al., Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women, Am J Epidemiol, 123, pp. 504-516, (1986)

[2]

Uusitupa M.I., Niskanen L.K., Siitonen O., Et al., 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects, Circulation, 82, pp. 27-36, (1990)

[3]

Kannel W.B., D'Agostino R.B., Wilson P.W., Et al., Diabetes, fibrinogen and risk of cardiovascular disease: The Framingham experience, Am Heart J, 120, pp. 672-676, (1990)

[4]

Laakso M., Lehto S., Epidemiology of macrovascular disease in diabetes, Diabetes Rev, 5, pp. 294-315, (1997)

[5]

Virmani R., Kolodgie F.D., Burke A.P., Et al., Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions, Artherioscler Thromb Vasc Biol, 20, pp. 1262-1275, (2000)

[6]

Osterman H., van de Loo J., Factors of the hemostatic system in diabetic patients, Haemostasis, 16, pp. 386-416, (1986)

[7]

Kwaan H.C., Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes, Diabetes, 41, SUPPL. 2, pp. 32-35, (1992)

[8]

Kario K., Mastuo T., Kobayashi H., Et al., Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients and microalbuminuria, Arterioscler Thromb Vasc Biol, 15, pp. 1114-1120, (1995)

[9]

Morishita E., Asakura H., Jakaji H., Et al., Hypercoagulability and high lipoprotein (a) levels in patients with type II diabetes mellitus, Atherosclerosis, 120, pp. 7-14, (1996)

[10]

Jones R.L., Fibrinopeptide-A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes, Diabetes, 34, pp. 836-843, (1985)

← 1 2 3 →